NuvOx Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-17. It has amended it 1 time. As of its latest filing, on 2026-09-16, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We intend to apply to list our common stock on the NYSE American under the symbol “NUOX.” This offering is contingent upon final approval by the NYSE American of our listing.From the S-1/A filed 2026-09-16
Shares offered
(2) The pro forma as adjusted balance sheet data reflects the items described in footnote (1) above and gives effect to our receipt of estimated net proceeds from the sale of 2,860,000 shares of common stock that we are offering in this offering at an assumed initial public offering price of the common stock of $7.00 per share, the midpoint of the price range on the cover page of this prospectus, and our receipt of approximately $17.4 million in net proceeds after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.From the S-1/A filed 2026-09-16
Use of proceeds
We expect to use the net proceeds from this offering as follows:From the S-1/A filed 2026-09-16
Net loss or income
We incurred net losses of $6.0 million and $14.0 million for the six months ended June 30, 2026 and June 30, 2025, respectively, and $16.6 million and $6.6 million for the years ended December 31, 2025 and December 31, 2024, respectively.From the S-1/A filed 2026-09-16
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-07-17 | Registration statement filed | S-1 |
| 2026-09-16 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for NuvOx Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.